Differential Gene Expression Analysis for Aromatase Inhibitors Treatment on Breast Cancer Patients

Breast cancer is the most common global malignancy and leading cause of deaths for women. Aromatase inhibitors are clinically recommended therapy disorders. However, resistance to aromatase therapies still occurs underlined molecular mechanisms poorly understood. The tumour specimens consisted inhibitor-sensitive inhibitor-resistant breast patients, who were compared differentially expressed genes patients generated related genetic network was explored. enriched cellular process signaling cassettes also in-depth investigated. Compared with 896 showed a significant differential expression. 621 significantly up-regulated 275 remarkably downregulated. From interaction network, including signal recognition particle 72, B-cell lymphoma-2 associated transcription factor 1, cathelicidin antimicrobial peptide defensin alpha 1B could be considered as key target treatment in patients. These processes involving immunoglobulin complex, cell division others while, drug metabolism other signalling study speculated several novel gene targets therapeutic initiated beneficial direction future research.